Loading…

Ali Health0241.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Information Technology Services

Alibaba-affiliated online pharmacy and healthcare platform selling medicines and running Tmall's health business.

≈ China's CVS/GoodRx hybrid, run inside the Alibaba ecosystemMomentum weak 34
Mkt cap
$5.51B
US dollars, full cap
Free float
36%
of shares outstanding
$/day
$27.2M
20-day average traded
Fwd P/E
18.1×
forward earnings
ROIC−WACC
+3.0 pp
WACC 16.9%
Hurdle
+4 pp
Req g minus delivered
Next earnings
13 days
1 Dec 2026
Close · HKDHK$2.73
1D-5.2%
1W-8.7%
1M-10.3%
3M-16.0%
6M-31.4%
YTD-46.0%
1Y-52.8%
ATR %3.8%
52w lowhigh65.4% off high

What Ali Health does

Alibaba-affiliated online pharmacy and healthcare platform selling medicines and running Tmall's health business.

Most sales come from selling medicines and health products itself through Tmall storefronts at a thin retail margin, while a smaller part is fees and marketing income from brands on Tmall Health. Alibaba Group is the controlling shareholder, and the business relies on its shoppers and delivery network.

In one line: China's CVS/GoodRx hybrid, run inside the Alibaba ecosystem.

Products and services

  • Online direct pharmacy sales
  • Tmall Health platform (marketplace)
  • Digital healthcare services (consultation)
  • Traceability/supply-chain services

Customers

  • Consumers buying medicine online
  • Pharma brands selling on Tmall

Where it sits in the supply chain

  • Healthcare
  • Digital health/pharmacy
  • Online drug retail & healthcare…

What could go right

  • Online pharmacy penetration growth
  • Chronic-disease medication delivery

What could go wrong

  • Regulatory tightening on online drug sales
  • Thin margins in direct pharmacy sales

Moat: narrow (scale, distribution, network effects). Alibaba traffic and logistics give it scale few standalone online pharmacies match.

Headquarters: Hangzhou, China · Founded: 2000 · Employees: 1,394

Named competitors

Ali Health at a glance

Size Ali Health (0241.HK) is a Hong Kong Health Care company (Information Technology Services) with a market value of $5.51B, the 235th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.73 on 18 Nov 2026.

Performance Over six months the shares fell 31.4%, against -6.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 14.0% over the last twelve months (peer median +24.1%); the operating margin is 5.3% (peer median 11.5%).

Valuation It trades at 18.1× forward earnings against a peer median of 12.0× (7th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.0 points above its cost of capital (16.9% WACC).

Next results Next results expected around 1 Dec 2026 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 940241.HK 70
Six months, rebased to 100: Ali Health against the median of its 20 peers (local-currency closes).

Ali Health financials

Reported figures in HKD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$37.7BHK$37.6BHK$33.0BHK$29.5BHK$30.6B
Revenue growth—+14%+12%-4%—
Gross profitHK$9.01BHK$9.02BHK$8.01BHK$6.44BHK$6.52B
EBITDAHK$2.07BHK$2.07BHK$1.64BHK$752MHK$21.3M
Net incomeHK$2.12BHK$2.13BHK$1.55BHK$965MHK$613M
Free cash flowHK$1.73BHK$1.71BHK$1.89BHK$1.42BHK$439M
Capital expenditureHK$10.00MHK$9.87MHK$20.4MHK$24.9MHK$6.77M
Total debtn/aHK$67.8MHK$38.1MHK$89.0MHK$88.9M

Quarterly statements and history in the cockpit →

Ali Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%999533471099087499261530682121961513612726071548187720963759269622680241.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Ali Health is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×100×200×300×999533471099087415306821154822680241.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ali Health is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%99953347377410990874219615131548269622680241.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ali Health is the large dot.

Ali Health competitors and peer comparison

Head to head with its named competitors (0241.HK vs 6618.HK vs 1833.HK vs 3690.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ali Health 0241.HK$5.51B-31%+14%5%18.1×20.2%
Jd Health 6618.HK$13.3B-15%+26%6%14.7×-0.9%
Ping An Healthcare and Technology 1833.HK$1.36B-47%+8%3%33.5×3.5%
Meituan-w 3690.HK$53.3B-16%+10%-12%256.3×n/a

How Ali Health compares with its peers

Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ali Health against its 20 peers (data as of 18 Nov 2026)
Measure0241.HKPeer medianRank in peer set
1-month return-10.3%-7.7%9th lowest of 21
6-month return-31.4%-6.8%4th lowest of 20
Distance from 52-week high-65.4%-37.9%lowest of 21
Revenue growth (TTM)+14.0%+24.1%7th lowest of 21
Operating margin5.3%11.5%8th lowest of 21
Forward P/E18.1×12.0×7th most expensive of 18
Growth the price implies (Req g, 7 yrs)20.2%1.2%5th most demanding of 15
Growth delivered (Del g)+16.2%+9.2%6th highest of 15
Hurdle (Req g minus delivered)+4.0 pp-10.1 pp5th most demanding of 15
ROIC minus cost of capital+3.0 pp+0.3 pp7th highest of 21
EV / EBITDA15.1×12.8×4th most expensive of 9
Net debt / EBITDA-5.7×-0.4×least indebted of 11

Peer table

Peer set: Sector in the same market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ali Health 0241.HKHong Kong$5.51B-31%+14%5%18.1×20.2%+16.2%
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Hangzhou Tigermed Consulting 3347.HKHong Kong$4.75B0%+22%10%59.8×25.4%+15.6%
Fameglow 3774.HKHong Kong$4.54Bn/a+36%11%n/a57.4%+48.4%
Sinopharm 1099.HKHong Kong$6.74B0%+3%3%6.2×-7.3%+4.0%
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%12.0×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%14.4×n/an/a
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%6.3×-9.7%+7.4%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%294.1×36.9%+19.8%
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%20.8×n/an/a
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
WuXi XDC Cayman 2268.HKHong Kong$10.4B+20%+42%28%35.8×20.6%+126.4%

Questions

Who are Ali Health's main competitors?
Named competitors: JD Health (6618.HK), Ping An Good Doctor (1833.HK), Meituan (pharmacy delivery) (3690.HK). The cockpit's measured peer set (sector in the same market, nearest in size) also includes RemeGen (9995.HK), Hangzhou Tigermed Consulting (3347.HK), Fameglow (3774.HK), Sinopharm (1099.HK), Guangzhou Baiyunshan Pharmaceutical (0874.HK), Akeso (9926.HK).
Is Ali Health expensive compared with its peers?
On forward p/e it trades at 18.1× against a peer median of 12.0×, 7th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Ali Health stock performed?
Over six months to 18 Nov 2026 the shares returned -31.4% against -6.8% for the median peer; over one year -52.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.